A Melbourne pharmaceutical company says its condom that kills certain STIs will soon be sold in Japan, one of the world’s largest condom markets.
Starpharma’s VivaGel condom contains a lubricant gel proven in laboratory settings to kill HIV, the herpes virus and HPV, the human papillomavirus that causes cervical cancer.
Starpharma said on Wednesday the condom had received final regulatory approval in Japan and will be sold by there by leading Japanese condom manufacturer Okamoto Industries under a licensing agreement.
Okamoto executive Keiji Ikeda said that condoms with functional gels represent the next wave in innovation in Japan, following a previous focus on condom thinness.
Starpharma CEO Dr Jackie Fairley called the regulatory approval ‘a key commercial milestone’ for the condom.
VivaGel condoms are also approved for sale in Australia and Canada, where they are sold as LifeStyles Dual Protect Condoms.
Just after noon Starpharma Holdings shares were trading down 8.5 cents, or 7.17 per cent, to $1.10.